A detailed history of Bank Of America Corp transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 1,360,925 shares of LCTX stock, worth $1.28 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,360,925
Previous 1,311,281 3.79%
Holding current value
$1.28 Million
Previous $1.94 Million 29.9%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$0.89 - $1.47 $44,183 - $72,976
49,644 Added 3.79%
1,360,925 $1.36 Million
Q1 2024

May 15, 2024

BUY
$0.86 - $1.48 $1.11 Million - $1.91 Million
1,287,428 Added 5397.34%
1,311,281 $1.94 Million
Q4 2023

Feb 14, 2024

SELL
$0.91 - $1.35 $44,004 - $65,281
-48,357 Reduced 66.97%
23,853 $25,000
Q2 2023

Aug 14, 2023

SELL
$1.26 - $1.53 $1.73 Million - $2.1 Million
-1,371,569 Reduced 95.0%
72,210 $101,000
Q1 2023

May 12, 2023

BUY
$1.2 - $1.53 $1.73 Million - $2.21 Million
1,442,750 Added 140208.94%
1,443,779 $2.17 Million
Q4 2022

Feb 10, 2023

BUY
$1.02 - $1.5 $22 - $33
22 Added 2.18%
1,029 $1,000
Q3 2022

Nov 14, 2022

SELL
$1.13 - $1.77 $11,292 - $17,687
-9,993 Reduced 90.85%
1,007 $1,000
Q1 2022

May 16, 2022

SELL
$1.21 - $2.48 $29,334 - $60,122
-24,243 Reduced 68.79%
11,000 $17,000
Q4 2021

Feb 08, 2022

BUY
$1.84 - $2.68 $43,517 - $63,384
23,651 Added 204.03%
35,243 $86,000
Q3 2021

Nov 15, 2021

SELL
$2.26 - $2.86 $13,191 - $16,693
-5,837 Reduced 33.49%
11,592 $29,000
Q2 2021

Sep 13, 2021

BUY
$2.17 - $3.0 $37,820 - $52,287
17,429 New
17,429 $49,000

Others Institutions Holding LCTX

About Lineage Cell Therapeutics, Inc.


  • Ticker LCTX
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 169,755,008
  • Market Cap $160M
  • Description
  • Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...
More about LCTX
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.